Hyperglycemia Treatment Market to Surpass USD 2,150.53 Million by 2036, Driven by Rising Diabetes Burden and Adoption of Advanced Glucose-Lowering Therapies

NEWARK, Del., USA | JUNE 01, 2026 - According to the latest analysis by Future Market Insights, the global hyperglycemia treatment market is witnessing robust growth, fueled by the rising prevalence of diabetes worldwide, increasing adoption of next-generation glucose-lowering therapies, and expanding healthcare access across emerging economies. As healthcare systems focus on improving glycemic control and reducing diabetes-related complications, demand for insulin therapies, oral antidiabetic drugs, GLP-1 receptor agonists, and SGLT-2 inhibitors continues to accelerate across hospitals, clinics, retail pharmacies, and homecare settings globally.

Featured Snippet: Key Market Insights

• Market Size (2025): USD 630.5 Million

• Estimated Market Value (2026): USD 704.9 Million

• Forecast Value (2036): USD 2,150.53 Million

• CAGR (2026-2036): 11.8%

• Incremental Opportunity (2026-2036): USD 1,445.63 Million

• Top Growth Markets: USA and South Korea

• Key Drivers: Rising diabetes prevalence, expanding adoption of GLP-1 receptor agonists and SGLT-2 inhibitors, improving healthcare access, growing awareness of glycemic management

• Leading Treatment Segment: Insulin Therapy

• Leading Administration Segment: Oral Administration

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16386

Market Overview: Growing Diabetes Burden Fuels Long-Term Market Expansion

The hyperglycemia treatment market is projected to grow from USD 704.9 million in 2026 to approximately USD 2,150.53 million by 2036, registering a CAGR of 11.8% during the forecast period.

Market growth is being driven by the increasing prevalence of diabetes and metabolic disorders, expanding treatment accessibility, and continuous innovation in glucose-lowering therapeutics. Healthcare providers are increasingly adopting advanced treatment protocols that combine insulin with oral and injectable therapies to improve glycemic outcomes and reduce cardiovascular and renal complications.

The rapid expansion of healthcare infrastructure across emerging economies and growing diagnosis rates are further strengthening long-term market demand.

Key Market Drivers

1. Rising Global Diabetes Prevalence

Increasing diabetes incidence across developed and emerging economies remains a major growth catalyst.

Key growth contributors include:

• Aging global population

• Rising obesity rates

• Sedentary lifestyles and dietary changes

• Growing incidence of Type 1 and Type 2 diabetes

As the diabetic patient population continues to expand, pharmaceutical demand for effective hyperglycemia management solutions is expected to rise significantly.

2. Growing Adoption of Next-Generation Glucose-Lowering Therapies

Clinical success of advanced drug classes is reshaping treatment protocols worldwide.

This trend is supported by:

• Increasing use of GLP-1 receptor agonists

• Expanding adoption of SGLT-2 inhibitors

• Proven cardiovascular and renal benefits

• Enhanced patient outcomes through combination therapies

Healthcare providers are increasingly prescribing these therapies earlier in treatment pathways to optimize long-term disease management.

3. Expanding Healthcare Access Across Emerging Markets

Improving healthcare infrastructure is increasing diagnosis and treatment rates globally.

Key factors include:

• Government-led diabetes screening programs

• Expanded health insurance coverage

• Improved access to pharmaceutical therapies

• Growing investments in primary healthcare services

Countries across Asia Pacific, Latin America, and the Middle East are creating significant growth opportunities for market participants.

👉 Speak to Analyst: Customize insights for your business strategy: https://www.futuremarketinsights.com/customization-available/rep-gb-16386

Segment Insights

Insulin Therapy Leads Treatment Segment Demand

The insulin therapy segment is expected to account for 42.5% of total treatment demand in 2026 due to:

• Essential role in Type 1 diabetes management

• Increasing utilization in advanced Type 2 diabetes

• Availability of rapid-acting and long-acting formulations

• Expanding biosimilar insulin adoption

Despite therapeutic innovation, insulin remains the cornerstone of glycemic control strategies globally.

Oral Administration Dominates Route of Administration

Oral administration is projected to account for 63.8% of market demand in 2026 owing to:

• Improved patient compliance

• Ease of administration

• Expanding range of oral antidiabetic drugs

• Growing adoption of DPP-4 inhibitors and SGLT-2 inhibitors

The convenience and effectiveness of oral therapies continue supporting widespread adoption.

Hospitals Remain the Largest End-Use Segment

Hospitals are expected to account for 46.9% of total market demand in 2026 due to:

• Acute hyperglycemia management requirements

• Increasing hospitalization of diabetic patients

• Growing insulin initiation programs

• Advanced inpatient monitoring capabilities

Hospitals continue serving as primary centers for emergency glycemic management and treatment optimization.

👉 Explore the Latest Healthcare Industry Analysis Now:
https://www.futuremarketinsights.com/industry-analysis/healthcare

Regional Insights

United States

The United States is projected to emerge as one of the fastest-growing markets, registering a CAGR of 11.9% through 2036, driven by:

• Advanced diabetes care infrastructure

• Strong adoption of GLP-1 receptor agonists

• Broad insurance coverage for innovative therapies

• Increasing integration of digital diabetes management solutions

The country continues leading innovation in diabetes treatment and patient care models.

South Korea

South Korea is expected to expand at a CAGR of 11.9% owing to:

• Rapid adoption of biologic therapies

• Strong national healthcare coverage

• Growing endocrinology specialization

• Expanding use of biosimilar insulin products

The country's evolving diabetes treatment landscape continues creating substantial market opportunities.

European Union

The EU is anticipated to grow at a CAGR of 11.8% due to:

• Favorable reimbursement policies

• Strong regulatory support for innovative therapies

• Growing aging population

• Expanding diabetes disease burden

European healthcare systems continue encouraging adoption of advanced glucose-lowering treatments.

Japan

Japan is projected to register a CAGR of 11.7% through 2036, supported by:

• Rising Type 2 diabetes prevalence

• Universal healthcare coverage

• Strong pharmaceutical innovation ecosystem

• Growing utilization of DPP-4 inhibitors

The country remains a major contributor to global diabetes treatment innovation.

United Kingdom

The UK is expected to grow at a CAGR of 11.7% through 2036, driven by:

• NHS-supported diabetes management programs

• Expanding primary care treatment initiatives

• NICE guideline-driven adoption

• Increasing use of combination therapy protocols

Healthcare policy support continues strengthening market growth prospects.

Technology and Research Trends

The hyperglycemia treatment market is evolving through advancements in:

• GLP-1 receptor agonist innovation

• SGLT-2 inhibitor development

• Long-acting insulin analogs

• Continuous glucose monitoring integration

• AI-enabled insulin dosing technologies

• Connected diabetes management platforms

Manufacturers are increasingly focusing on improving treatment efficacy, patient adherence, and long-term disease management outcomes.

👉 Get Full Report Access for Detailed Analysis: https://www.futuremarketinsights.com/reports/hyperglycemia-treatment-market

Challenges in the Market

High Cost of Advanced Therapies

The market continues facing pressure from:

• Premium pricing of biologic therapies

• Reimbursement constraints

• Healthcare budget limitations

• Affordability concerns in developing economies

Cost-related barriers remain a challenge for broader treatment accessibility.

Treatment Adherence and Access Gaps

Additional challenges include:

• Limited healthcare access in underserved regions

• Delayed diabetes diagnosis

• Medication adherence issues

• Variability in treatment availability

Industry stakeholders continue investing in affordability initiatives and patient support programs to improve outcomes.

Opportunities: Digital Health and Precision Diabetes Management

The market is unlocking new opportunities through:

• Integration of digital health technologies

• Expansion of personalized diabetes care

• Connected glucose monitoring ecosystems

• Growing demand for combination therapies

• Increasing adoption of value-based healthcare models

Organizations combining pharmaceutical innovation with digital diabetes management solutions are expected to gain significant competitive advantages.

Competitive Landscape

The hyperglycemia treatment market remains highly competitive, with leading companies focusing on insulin innovation, advanced biologics, and integrated diabetes care solutions.

Leading Companies

• Novo Nordisk A/S

• Eli Lilly and Company

• Sanofi S.A.

• Merck & Company Inc.

• Abbott

• Medtronic

• Johnson & Johnson Services Inc.

• Bayer AG

These companies continue investing in product innovation, strategic partnerships, clinical research, and market expansion initiatives to strengthen their global positions.

👉 Unlock high-growth opportunities with FMI's niche business market insights: https://www.futuremarketinsights.com/industry-analysis

Recent Developments

• In 2025, Novo Nordisk received expanded regulatory approvals for semaglutide across multiple diabetes and cardiovascular risk reduction indications in Europe and Asia.

• In 2025, Eli Lilly expanded reimbursement access for tirzepatide (Mounjaro) across major healthcare markets through new payer agreements in the USA and Europe.

Conclusion: Therapeutic Innovation and Expanding Healthcare Access to Sustain Market Growth

The hyperglycemia treatment market continues evolving around advances in diabetes therapeutics, growing healthcare accessibility, and increasing awareness of glycemic management. Rising demand for effective glucose-lowering therapies, expanding adoption of biologics, and ongoing digital health integration are expected to sustain market growth through 2036.

As healthcare systems increasingly focus on reducing diabetes-related complications and improving patient outcomes, organizations with strong therapeutic portfolios, innovative treatment technologies, and broad market reach are expected to lead the next phase of growth in the global hyperglycemia treatment industry.

* FAQs

1. How large is the hyperglycemia treatment market in 2025?

The global hyperglycemia treatment market was valued at USD 630.5 million in 2025.

2. What will be the hyperglycemia treatment market size by 2036?

The market is projected to reach USD 2,150.53 million by 2036.

3. What growth rate is expected for the hyperglycemia treatment market?

The market is expected to grow at a CAGR of 11.8% from 2026 to 2036.

4. Which treatment segment leads the hyperglycemia treatment market?

Insulin therapy is expected to lead with a 42.5% market share in 2026.

5. Which mode of administration dominates the hyperglycemia treatment market?

Oral administration is expected to lead with a 63.8% share in 2026.

* Have a Look at Related Research Reports on the Healthcare Domain

· Genital Herpes Treatment Market - https://www.futuremarketinsights.com/reports/genital-herpes-treatment-market

· Menopause Induced Insomnia Treatment Market - https://www.futuremarketinsights.com/reports/menopause-induced-insomnia-treatment-market

· Endometriosis Treatment Market - https://www.futuremarketinsights.com/reports/endometriosis-treatment-market

· Venous Thromboembolism Treatment Market - https://www.futuremarketinsights.com/reports/venous-thromboembolism-treatment-market

· Canine Arthritis Treatment Market - https://www.futuremarketinsights.com/reports/canine-arthritis-market

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com

Future Market Insights is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. Headquartered in Newark, with a global delivery center in Pune and offices in the United Kingdom and United Arab Emirates, FMI delivers actionable insights across industries including food & beverage, healthcare, chemicals, and consumer goods.
An ESOMAR-certified organization, FMI provides data-driven insights to support strategic decision-making for global businesses.

This release was published on openPR.